A new Lancet commission report proposes reframing obesity as a distinct disease spectrum divided into 'preclinical' and 'clinical' stages, moving beyond reliance on BMI. This diagnostic shift aligns with recent FDA guidance prioritizing pharmacological treatments, such as GLP-1 receptor agonists, over lifestyle changes alone. The reclassification aims to improve clinical decision-making regarding which patients require medical intervention for organ dysfunction caused by excess adiposity.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.